HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PLSE
Pulse Biosciences, Inc.
There isn't enough reported data to score PLSE yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PLSE Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
PLSE's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PLSE PE Valuation
PLSE has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PLSE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PLSE's losses to grow, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over PLSE on earnings, with more consistent year-over-year improvement.
PLSE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.21 | -$0.06 |
| Q2 2026 | -$1.18 | -$0.11 |
| Q1 2026 | -$1.10 | -$0.11 |
| Q4 2025 | -$1.08 | -$0.16 |
| Q3 2025 | -$1.15 | -$0.31 |
| Q2 2025 | -$1.07 | -$0.25 |
| Q1 2025 | -$0.99 | -$0.15 |
| Q4 2024 | -$0.92 | $0.00 |
PLSE is still losing money, but less than at its worst: $1.21 per share over the past year, against $2.35 at its worst in early 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PLSE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over PLSE on profitability, with a higher operating margin.
PLSE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $395K | +359% |
PLSE's revenue is recovering but still below its 2021 peak: $395,000 last quarter, up 359% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6150% | +17533 points |
| Q2 2026 | -5823% | N/A |
| Q1 2026 | -4776% | N/A |
| Q4 2025 | -6914% | N/A |
| Q3 2025 | -23683% | N/A |
| Q2 2022 | -5288% | N/A |
| Q1 2022 | -3890% | N/A |
| Q4 2021 | -1826% | N/A |
PLSE's operating margin was −6150% last quarter, up 17533 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PLSE on cash generation, producing positive trailing cash flow while its opponent burns cash.
PLSE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.4M | -$2.3M |
| Q2 2026 | -$18.8M | -$5.9M |
| Q1 2026 | -$14.6M | -$1.1M |
| Q4 2025 | -$14.9M | -$5.7M |
| Q3 2025 | -$13.1M | -$4M |
| Q2 2025 | -$12.9M | -$4.5M |
| Q1 2025 | -$13.6M | -$3.8M |
| Q4 2024 | -$9.2M | -$2.4M |
PLSE has burned cash in almost every quarter: −$64M over the past year, against −$49M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PLSE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PLSE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +2.7M shares |
| 1 year | +6.7% | +4.5M shares |
| 3 years | +31% | +17M shares |
| 5 years | +143% | +42.3M shares |
| Available history | +246% | +51.1M shares |
PLSE has 72M diluted shares, up 6.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PLSE Net Leverage
PLSE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PLSE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.4 | Neutral |
| Stochastic | 72.2 | Neutral |
PLSE's weekly RSI is 62 (neutral) and its Stochastic is 72 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PLSE PE vs Healthcare Sector
PLSE has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PLSE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $51.1 | 2.3% above |
| 20 week MA | $45.2 | 16% above |
| 50 week MA | $30.1 | 74% above |
| 100 week MA | $23.5 | 122% above |
| 200 week MA | $16.5 | 217% above |
PLSE has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PLSE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.7 | $21.1 | +55% |
| 2021 | $21.1 | $15.5 | -27% |
| 2022 | $15.5 | $2.53 | -84% |
| 2023 | $2.53 | $12.2 | +384% |
| 2024 | $12.2 | $18.0 | +47% |
| 2025 | $18.0 | $14.4 | -20% |
| 2026 YTD | $14.4 | $52.3 | +263% |
PLSE has the edge over HIMS on returns for 2026, with the stronger performance.